Insulin inhaler: Sanofi signed a license agreement – Boursorama

Insulin inhaler: Sanofi signed a license agreement – Boursorama

Sanofi has signed an exclusive licensing agreement to globally with the American biotechnology company MannKind Corporation for its insulin inhalation powder (AFP / File / Eric Piermont)

The pharmaceutical group Sanofi has signed an exclusive licensing agreement globally , the amount could reach $ 775 million, with the American biotechnology company MannKind Corporation for its insulin powder for inhalation, said Monday the two companies.

This product, called Afrezza, which “is a new insulin inhaler quick to the treatment of diabetes type 1 and type 2 adult action “is to be launched in the United States in the first quarter of 2015, said the joint statement.

MannKind Corporation will receive an upfront payment of $ 150 million and subsequently milestone payments that could reach a total of $ 775 million if “specific targets in terms of development, regulatory and sales thresholds” are met.

States in the development and commercialization of Afrezza, MannKind Sanofi and will share all losses and profits to the tune of 65% and 35%.

drugmaker also agreed to make an advance of MannKind’s share of spending up to $ 175 million.

The collaboration agreement provides that Sanofi will be responsible for developing business regulatory and marketing of the product. Under a separate agreement, MannKind Afrezza will manufacture at its plant in Danbury, Connecticut (north-eastern United States).

“Afrezza adds to our portfolio of solutions for the Diabetes is growing, “said Pierre Chancel, Senior Vice-President of the diabetes division of Sanofi, said in the statement.

” She is uniquely positioned to provide patients a new treatment option based on insulin to manage their diabetes without the need for multiple daily injections, “said he said.

” The two companies also plan to work together to increase production capacity if that should was needed to meet global demand, “the statement said.

Copyright © 2014 AFP. All rights of reproduction and distribution reserved.

All information displayed on this section (dispatches, photographs, logos) are protected by intellectual property rights owned by AFP. Therefore, none of this information may be reproduced, modified, transmitted, redistributed, translated, sold, exploited commercially or reused in any way whatsoever without the prior written consent of the AFP. AFP shall not be held liable for any delays, errors, omissions, which may not be excluded nor for the consequences of actions or transactions made on the basis of this information.

Read also